Q2 2025 NeuroOne Medical Technologies Corp Earnings Call Transcript
Key Points
- NeuroOne Medical Technologies Corp (NMTC) reported a 97% increase in product revenue to $4.7 million for the first half of fiscal 2025.
- The company achieved a significant improvement in product gross margins, reaching 57.9%, more than double the margin from the previous year.
- NeuroOne Medical Technologies Corp (NMTC) has no debt and anticipates being fully funded through at least fiscal year 2026.
- The OneRF ablation system has shown clinical success, with the majority of patients treated remaining seizure-free.
- The company has expanded its strategic partnership with Zimmer Biomet, leveraging their extensive distribution network to drive product adoption.
- Product revenue in the second quarter of fiscal 2025 remained flat at $1.4 million compared to the same quarter in the previous year.
- The company experienced a sequential decline in product revenue due to the completion of initial stocking orders to Zimmer Biomet.
- Operating expenses increased slightly to $3.5 million in the second quarter of fiscal 2025.
- NeuroOne Medical Technologies Corp (NMTC) reported a net loss of $2.3 million for the second quarter of fiscal 2025.
- The company has not yet commercialized its products in international markets, representing an untapped revenue opportunity.
Good day, ladies and gentlemen. Welcome to the second-quarter of fiscal year 2025 financial results conference call for NeuroOne Medical Technologies Corporation. Today's call will be conducted by the company's Chief Executive Officer, Dave Rose; and Ron McClurg, the company's Chief Financial Officer. Chris Volker, the company's Chief Operating Officer, will also be in attendance.
Before I turn the call over to Mr. Rosa, I'd like to remind you that this conference call will include forward-looking statements within the meaning of US federal securities laws with respect to future operations, financial results, events, trends and performance, which are based on management's beliefs and assumptions as of today's call or other specified date.
Forward-looking statements, including statements regarding our fiscal 2025 guidance may involve known and unknown risks, uncertainties and other factors, which may cause actual results to differ materially from those expressed or implied by such statements. See NeuroOne's financial results press release and SEC filings for information regarding specific
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
